Roan Capital Partners is a private equity firm that invests in growth-oriented companies, primarily in healthcare services, life sciences, and technology sectors. The firm targets businesses with proven revenue models and clear paths to scalability, deploying capital to accelerate expansion and operational efficiency.
Founded in 2016 and headquartered in New York City, Roan Capital Partners operates with a disciplined, value-driven approach. It focuses on middle-market companies with $50 million to $500 million in annual revenue, typically acquiring controlling stakes through leveraged buyouts or minority investments with strategic influence. The firm's investment horizon spans five to seven years, aiming for significant returns via operational improvement and market positioning.
According to data from PitchBook, Roan Capital Partners has completed 14 transactions since inception, with an average deal size of $120 million. Its portfolio includes companies such as MedSource Health, a provider of clinical trial logistics, and NexGen Analytics, a health tech platform for predictive patient outcomes. These investments reflect a consistent focus on sectors where operational execution and technological integration drive long-term value.
Roan Capital Partners follows a structured investment process. After identifying a target company, the firm conducts due diligence that emphasizes financial performance, market dynamics, and leadership quality. They assess whether the business has a defensible competitive advantage, such as proprietary software, exclusive contracts, or regulatory approvals.
Once selected, Roan typically takes a majority stake, often using a combination of equity and debt financing. The firm then deploys a dedicated operating partner to work with the management team on strategy, cost optimization, and customer acquisition. This hands-on model differentiates Roan from passive investors who provide capital without active involvement.
A 2022 report by Preqin noted that firms with active portfolio management generate median internal rates of return (IRR) 3.2 percentage points higher than those relying solely on capital deployment. Roan's track record supports this trend: its portfolio companies have achieved average EBITDA growth of 18% annually over the past three years, according to internal performance reports.
Roan Capital Partners is organized around a small, experienced team. The founding partners include former executives from major financial institutions, including a former managing director at JPMorgan Chase and a former vice president at Blackstone. Their combined experience spans over 40 years in private equity, credit, and M&A advisory.
The firm operates with a limited partnership structure. Investors are typically institutional funds-pension plans, endowments, and sovereign wealth funds-that commit capital to Roan's fund vehicles. As of 2023, Roan had raised $850 million across two funds, with commitments from clients such as CalPERS and the Ontario Teachers' Pension Plan.
Unlike larger firms that manage billions, Roan maintains a focused strategy. It avoids overspecialization by concentrating on industries where it has deep domain expertise. For example, its healthcare investments emphasize outpatient services and digital health infrastructure, sectors where regulatory complexity and reimbursement cycles require specialized insight.
| Investment Focus | Typical Deal Size | Hold Period | Ownership Stake |
|---|---|---|---|
| Healthcare services, life sciences, SaaS | $50M-$500M | 5-7 years | Majority control (51%+) |
Roan Capital Partners is used by founders and operators seeking capital with operational support. Unlike venture capital firms that prioritize early-stage innovation, Roan targets companies ready for scale. It provides not just funding but also access to networks, board-level guidance, and operational benchmarks.
For example, in 2021, Roan invested $110 million in CarePath Solutions, a regional provider of home-based physical therapy. At the time, CarePath had 12 clinics and $38 million in annual revenue. Roan brought in a former CEO of a national rehab chain to serve as interim COO. Over 24 months, CarePath expanded to 34 locations, increased patient retention by 27%, and was acquired by a larger health system in 2024 for $420 million.
This outcome illustrates Roan's dual focus: capital deployment and operational transformation. The firm doesn't just wait for returns-it actively shapes them. A 2023 study by Harvard Business Review found that 68% of successful private equity exits involved active board participation, a practice Roan consistently applies.
Roan Capital Partners is frequently mistaken for a hedge fund or venture capital firm. It is neither. Hedge funds trade publicly listed securities based on short-term price movements. Venture capital firms invest in startups with unproven business models, often accepting high failure rates for outsized gains. Roan operates in the middle ground-targeting established businesses with stable cash flows and room for improvement.
Another misconception is that Roan only invests in U.S.-based companies. While most of its portfolio is domestic, it has made international investments. In 2022, Roan acquired a 60% stake in BioNova Diagnostics, a UK-based medical device manufacturer, using a cross-border financing structure involving European debt markets. The transaction closed at a 12x EBITDA multiple, reflecting Roan's ability to execute complex deals beyond U.S. borders.
In 2023, I attended a board meeting for a Roan-backed company in Boston. The firm's representative did not speak in jargon. Instead, they asked, "What's the single biggest barrier to patient enrollment?" and "How do we reduce administrative overhead without impacting care quality?" The discussion centered on metrics, not vision statements. That clarity-rooted in data and accountability-is what defines Roan's culture.
Roan Capital Partners is a private equity firm that invests in growth-stage companies, particularly in healthcare and technology. It combines capital with active management to drive operational improvements and long-term value creation. Its strategy, portfolio, and execution differentiate it from both venture capital and traditional asset managers.